919 results match your criteria Lupus Erythematosus Subacute Cutaneous


Chronic cutaneous lupus erythematosus induced by 5-fluorouracil.

Authors:
Philip R Cohen

Expert Rev Clin Pharmacol 2020 Jul 7. Epub 2020 Jul 7.

San Diego Family Dermatology , National City, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2020.1793669DOI Listing

Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: A Case Report and Review.

Authors:
Philip R Cohen

Cureus 2020 Apr 25;12(4):e7828. Epub 2020 Apr 25.

Dermatology, San Diego Family Dermatology, National City, USA.

Systemic fluorouracil agents include not only 5-fluorouracil (5FU), but also capecitabine, tegafur, and uracil/tegafur (UFT). Systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE), and discoid lupus erythematosus (DLE) are subtypes of lupus erythematosus; drug-induced lupus erythematosus can also present in each of these subtypes. This report describes the case of a 65-year-old woman with systemic 5FU-induced DLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249746PMC

Secukinumab-induced subacute cutaneous lupus erythematosus.

Dermatol Ther 2020 May 3;33(3):e13417. Epub 2020 May 3.

Dermatology and Venereology Department, University of Trieste, Ospedale Maggiore di Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13417DOI Listing

Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.

J Dermatol 2020 Jun 15;47(6):e217-e219. Epub 2020 Mar 15.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15316DOI Listing

Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review.

J Cutan Pathol 2020 Jul 13;47(7):654-658. Epub 2020 Mar 13.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is an uncommon but well-described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI-SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13673DOI Listing

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus.

Lupus Sci Med 2020 27;7(1):e000364. Epub 2020 Jan 27.

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Objective: The severity and disease course of cutaneous lupus erythematosus (CLE) are highly variable. Consequently, outcome measures for CLE clinical improvement are heterogeneous, complicating treatment decisions and therapeutic development. This study characterises CLE outcome measures and identifies the influence of clinical improvement thresholds on strengths of associations with patient demographic and clinical factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2019-000364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008708PMC
January 2020

MicroRNA Expression in Cutaneous Lupus: A New Window to Understand Its Pathogenesis.

Mediators Inflamm 2019 30;2019:5049245. Epub 2019 Dec 30.

Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.

Background: The role of miRNAs in the pathogenesis of cutaneous lupus has not been studied.

Objective: It was to assess the levels of a selected panel of circulating miRNAs that could be involved in the regulation of the immune response, inflammation, and fibrosis in cutaneous lupus.

Methods: It was a cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5049245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012207PMC

Drug-induced anti-Ro positive subacute cutaneous lupus in a man treated with olmesartan.

Dermatol Online J 2019 Dec 15;25(12). Epub 2019 Dec 15.

Hospital Corporation of America/University of South Florida Morsani College of Medicine Graduate Medical Education: Department of Dermatology, Largo Medical Center Program, Largo, FL.

A 66-year-old man presented to the outpatient dermatology clinic with a chief complaint of a pruritic rash on his upper trunk and proximal upper extremities, which had been present for three weeks. Upon examination, he was found to have an erythematous, annular, and polycyclic eruption on the chest, upper back, and proximal extremities. A clinical diagnosis of subacute cutaneous lupus erythematosus (SCLE) was made. Read More

View Article

Download full-text PDF

Source
December 2019

Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.

Dermatol Online J 2019 Nov 15;25(11). Epub 2019 Nov 15.

Department of Dermatology, University of California San Diego, La Jolla, CA.

Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs. It presents weeks to months after initiation of the culprit medication. The eruption is typically in a photodistribution and it is marked by positive serology to anti-Ro (SSA) antibody. Read More

View Article

Download full-text PDF

Source
November 2019

Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study.

Rheumatol Ther 2020 Mar 1;7(1):201-213. Epub 2020 Feb 1.

BioPharmaceuticals Medical, AstraZeneca, Luton, UK.

Introduction: Online health communities and research networks such as PatientsLikeMe (PLM) capture patient perspectives of diseases, including systemic lupus erythematosus (SLE). We performed a retrospective observational study of data provided by patients in the PLM SLE community to characterize demographics, clinical characteristics, patient experience, and symptom impact.

Methods: Adults who registered with PLM in 2011-2017 and reported SLE diagnosis and treatment with one or more SLE-related drug (antimalarials, immunosuppressives, corticosteroids, calcineurin inhibitors, or biologics) were included in the analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-020-00195-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021880PMC

Central Nervous System Systemic Lupus Erythematosus (CNS-SLE) Vasculitis Mimicking Lewy Body Dementia: A Case Report Emphasizing the Role of Imaging With an Analysis of 33 Comparable Cases From the Scientific Literature.

J Geriatr Psychiatry Neurol 2020 Jan 30:891988720901788. Epub 2020 Jan 30.

Department of Psychiatry, University of California, San Diego, CA, USA.

Introduction: Neuropsychiatric symptoms occur in 30% to 40% of patients living with systemic lupus erythematosus (SLE). Brain imaging may play a pivotal role in determining the etiology as it did for the case presented here.

Methods: A new case of central nervous system (CNS) SLE is presented along with an analysis of 33 comparable cases from the scientific literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0891988720901788DOI Listing
January 2020

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events.

Dermatol Ther (Heidelb) 2020 Feb 21;10(1):221-229. Epub 2020 Jan 21.

San Diego Family Dermatology, National City, CA, USA.

Anastrozole is an aromatase inhibitor. Anastrozole competitively inhibits the aromatase enzyme, which synthesizes estrogen. It is used for estrogen receptor-positive breast cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-020-00353-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994559PMC
February 2020

Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus.

Int J Dermatol 2020 Apr 20;59(4):e118-e120. Epub 2020 Jan 20.

Department of Dermatology, Bichat Hospital, APHP, University Paris 7, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14773DOI Listing

Three cases of subacute cutaneous lupus erythematosus associated with malignancy: a late paraneoplastic phenomenon.

Clin Exp Dermatol 2020 Jul 3;45(5):607-608. Epub 2020 Feb 3.

Department of Dermatology, Royal Cornwall Hospital NHS Trust, Tresliske, Truro, Cornwall, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14176DOI Listing

Childhood subacute cutaneous lupus erythematosus associated with transaminitis.

Clin Exp Dermatol 2020 Jul 13;45(5):593-595. Epub 2020 Jan 13.

Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14160DOI Listing

Subacute cutaneous lupus erythematosus with a possible paraneoplastic association with melanoma.

Authors:
Jesse Hirner

BMJ Case Rep 2019 Nov 28;12(11). Epub 2019 Nov 28.

Dermatology, University of Missouri, Columbia, Missouri, USA

A 52-year-old man was referred to our dermatology clinic for a diagnosis of melanoma. At the time, his melanoma was excised he developed an annular, polycyclic, scaling eruption consistent with subacute cutaneous lupus erythematosus (SCLE). Skin biopsy and laboratory evaluation confirmed this diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-230558DOI Listing
November 2019

Capecitabine-induced Subacute Cutaneous Lupus Erythematosus.

An Bras Dermatol 2019 Sep - Oct;94(5):618-619. Epub 2019 Sep 30.

Department of Reumatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abd.2019.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857571PMC
December 2019

Cutaneous lupus erythematosus induced by drugs - novel insights.

Expert Rev Clin Pharmacol 2020 Jan 2;13(1):35-42. Epub 2019 Dec 2.

Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA.

: There is a growing list of drugs implicated in inducing both subacute and chronic forms of cutaneous lupus erythematosus. It is important to recognize these drugs in order to quickly treat patients with drug induced disease.: This paper reviews the current literature describing drugs implicated in causing cutaneous lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2020.1698290DOI Listing
January 2020

Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.

Dermatol Online J 2019 Oct 15;25(10). Epub 2019 Oct 15.

Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL.

Checkpoint inhibitor immunotherapy, including ipilimumab and nivolumab, is associated with numerous immune-related adverse events including dermatitis, pruritus, hepatitis, diarrhea, and hypophysitis. As the number of patients undergoing immunotherapy treatment increases, however, rare and unusual immune-related adverse events are observed. Many of these resemble known autoimmune phenomenon, such as subacute lupus erythematosus and myositis. Read More

View Article

Download full-text PDF

Source
October 2019

UV radiation exposure in welders: impact on the skin and eyes.

Cutis 2019 Sep;104(3):E16-E18

Novi Dermatology, Michigan, USA.

Arc welding is an occupation with exposure to intense bursts of UV radiation (UVR). Although industrial settings may be aware of UV light exposure during welding, physicians may be unaware of this source. We report 3 welders with skin diseases that may have been caused or exacerbated by occupational UV light exposure: refractory subacute cutaneous lupus erythematosus, diffuse actinic damage spared by the area protected by safety goggles, and squamous cell carcinoma developed outside of the area protected by a face shield. Read More

View Article

Download full-text PDF

Source
September 2019
2 Reads

Perplexing Pruritic Plaques and Pancytopenia: Subacute Cutaneous Lupus.

Am J Med 2020 03 21;133(3):297-300. Epub 2019 Oct 21.

Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Fla.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2019.09.022DOI Listing
March 2020
1 Read

Clinicopathologic comparison of Rowell syndrome, erythema multiforme, and subacute cutaneous lupus erythematosus.

J Am Acad Dermatol 2019 12 13;81(6):1435-1438. Epub 2019 Jun 13.

Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.06.008DOI Listing
December 2019
1 Read

Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus associated with lung carcinoma.

BMJ Case Rep 2019 Oct 13;12(10). Epub 2019 Oct 13.

Department of Dermatology, Hospital and University Centre of Coimbra, Coimbra, Portugal.

Specific vesiculobullous skin lesions in lupus erythematosus (LE) are rare and must be differentiated from toxic epidermal necrolysis (TEN), TEN-like dermatoses and other vesiculobullous conditions. We report a patient with typical subacute cutaneous lupus erythematous that progressed with large sheet-like areas of epidermal detachment and Nikolsky sign resembling TEN. She had a serological profile suggestive of underlying connective tissue disease, histological findings of interface dermatitis with a lymphocytic infiltrate, positive direct immunofluorescence, resolution with immunomodulation and lack of a culprit drug, features observed in TEN-like cutaneous lupus erythematous. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-231152DOI Listing
October 2019
2 Reads

Suspected inflammatory rheumatic diseases in patients presenting with skin rashes.

Best Pract Res Clin Rheumatol 2019 08 1;33(4):101440. Epub 2019 Oct 1.

Clinic of Dermatology, University Hospital of Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal. Electronic address:

Skin lesions occur, often at very early stages, in many of the most frequent inflammatory rheumatic diseases such as in systemic lupus erythematosus (SLE), dermatomyositis (DM), systemic sclerosis (SSc), Sjögren's syndrome, rheumatoid arthritis (RA), and psoriatic arthritis. It is important to recognize the different specific cutaneous lesions in SLE (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2019.101440DOI Listing
August 2019
4 Reads

[Immunohistochemical analysis for C3d, C4d, IgG, IgG4, and CD123 in diagnosis of autoimmune skin diseases].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2019 Aug;44(8):878-884

Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha 410011, China.

Objective: To assess the value of immunohistochemical analysis for expressions of C3d, C4d, IgG, IgG4, and CD123 in the diagnosis of autoimmune skin diseases.
 Methods: We investigated the expressions of C3d, C4d, IgG, IgG4, and CD123 in paraffin-embedded, formalin-fixed tissues from 27 lupus erythematosus cases, including 8 discoid lupus erythematosus (DLE) cases, 4 subacute cutaneous lupus erythematosus (SCLE) cases, and 15 systemic lupus erythematosus (SLE) cases. Tissues from 15 dermatomyositis (DM) cases, 15 bullous pemphigoid (BP) cases, and 15 pemphigus cases were examined by immunohistochemical analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2019.180800DOI Listing
August 2019
2 Reads

Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus.

Exp Dermatol 2019 11 29;28(11):1348-1352. Epub 2019 Sep 29.

Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon.

Neutrophil extracellular traps (NETs) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, little is known about the implication of NETs in cutaneous lupus. In this case series of 30 patients, we compared the amounts of neutrophils producing NETs in cutaneous lesions of different subtypes of lupus (5 with discoid lupus or DLE, 5 with subacute cutaneous lupus or SCLE, 11 with acute cutaneous SLE, 7 with lupus panniculitis and 2 with chilblains). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14040DOI Listing
November 2019
6 Reads

Management of cutaneous manifestations of lupus erythematosus: A systematic review.

Semin Arthritis Rheum 2020 02 12;50(1):95-127. Epub 2019 Aug 12.

Department of Rheumatology, St Vincent's Hospital, Melbourne, Australia; The University of Melbourne, Australia. Electronic address:

Background: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating, causing significant psychological distress, and sometimes scarring.

Objectives: We sought to comprehensively present the evidence for different treatment modalities in patients with cutaneous manifestations of lupus erythematosus (LE).

Methods: Medline, Embase, Scopus and Cochrane CENTRAL were searched electronically from 1990 to March 2019, using keywords related to cutaneous lupus and synonyms and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.07.010DOI Listing
February 2020
4 Reads

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus.

Lupus 2019 Oct 14;28(11):1320-1328. Epub 2019 Sep 14.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.

Objectives: The objectives of this study were to assess the reliability of a novel objective outcome measure, laser Doppler imaging (LDI), its validity against skin biopsy histology and other clinical instruments, including localized cutaneous lupus disease area and severity index (L-CLASI) and visual analogue scale (VAS) score of photographs, and its responsiveness to clinical change with therapy.

Methods: A prospective observational cohort study was conducted in 30 patients with active cutaneous lupus erythematosus (CLE). At baseline and 3 months, disease activity was assessed using L-CLASI and a high resolution LDI system by two assessors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319873977DOI Listing
October 2019
2 Reads

Proton Pump Inhibitor-Induced Subacute Cutaneous Lupus Erythematosus.

J Allergy Clin Immunol Pract 2020 Jan 16;8(1):326-327. Epub 2019 Aug 16.

Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.07.025DOI Listing
January 2020
2 Reads

Molecular Profiling of Cutaneous Lupus Lesions Identifies Subgroups Distinct from Clinical Phenotypes.

J Clin Med 2019 Aug 17;8(8). Epub 2019 Aug 17.

Division of Rheumatology, Department of Internal medicine, University of Michigan, Ann Arbor, MI 48109, USA.

Cutaneous lupus erythematosus (CLE) is a common manifestation of systemic lupus erythematosus (SLE), and CLE can also develop without systemic involvement. CLE can be difficult to treat and negatively contributes to quality of life. Despite the importance of CLE, our knowledge of what differentiates cutaneous lupus subtypes is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8081244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723404PMC
August 2019
2 Reads

Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus.

Australas J Dermatol 2020 Feb 13;61(1):e113-e114. Epub 2019 Aug 13.

The County Hospital, Hereford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13133DOI Listing
February 2020

Rowell's Syndrome Triggered by Omeprazole.

Acta Dermatovenerol Croat 2019 Jun;27(2):124-126

Lyubomir Dourmishev MD, PhD, Department of Dermatology and Venereology, Medical University - Sofia, Bulgaria, 1st Georgi Sofiiski Blvd,. 1431 Sofia, Bulgaria.

Dear Editor, Rowell's syndrome is a rare disease, characterized by the appearance of erythema multiforme (EM)-like lesions in patients with lupus erythematosus. It was initially reported by Rowell (1) in 1963 and its existence as a separate clinical entity is currently under debate (2,3). A few cases may have been induced by drugs such as systemic antimycotics, antibiotics, anticonvulsants, and more recently proton pump inhibitors (PPIs). Read More

View Article

Download full-text PDF

Source
June 2019
7 Reads
0.581 Impact Factor

An atypical presentation of subacute cutaneous lupus erythematous.

Rheumatology (Oxford) 2019 12;58(12):2142

Department of Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez144DOI Listing
December 2019
1 Read

Cutaneous effects of antihypertensive drugs.

G Ital Dermatol Venereol 2020 Apr 12;155(2):202-211. Epub 2019 Jun 12.

Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.

Introduction: Treatment with antihypertensive drugs may be associated with different dermatological adverse reactions.

Evidence Acquisition: We systematically reviewed the literature available on the MEDLINE (PubMED) databases, up to July 2018. We searched for the terms "calcium-channel blockers" or "angiotensin-converting enzyme inhibitors" or "angiotensin II receptors blockers" or "diuretics" or "beta blockers" AND "dermatological effects" or "skin disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06360-0DOI Listing
April 2020
25 Reads

Subacute Cutaneous Lupus Erythematosus in a Male Patient on Multiple Antiepileptics Unmasked by Melatonin.

Authors:
Gerhard Eichhoff

J Clin Rheumatol 2019 May 24. Epub 2019 May 24.

From the Capital and Coast District Health Board, Dermatology Service, Wellington Hospital, Wellington, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001087DOI Listing
May 2019
5 Reads

Heterogeneous lupus-specific lesions and treatment outcome, in a single patient, over a period of time.

Clin Case Rep 2019 May 22;7(5):865-871. Epub 2019 Mar 22.

Unidade de Doenças Auto-imunes/Serviço de Medicina 7.2, Hospital de Curry Cabral Centro Hospitalar Universitário de Lisboa Central Lisboa Portugal.

The report highlights the importance of strict clinico-histological correlations when skin biopsies are performed in diagnostic doubt in systemic lupus erythematosus. Furthermore, PUVA is never indicated in autoimmune conditions involving photosensitivity, due to high potential for internal and cutaneous aggravation of the disease, as the authors observed in this case. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509922PMC
May 2019
5 Reads

The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients.

Asian Pac J Allergy Immunol 2019 Apr 23. Epub 2019 Apr 23.

Center of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology.

Background: Juvenile systemic lupus erythematosus (JSLE) and adult SLE (ASLE) patients present with different clinical manifestations, but it is unknown if there are differences in their antinuclear autoantibody (ANA) profiles or if staining patterns are associated with specific autoantibodies and clinical manifestations.

Objective: To determine whether distinct types and numbers of ANA-staining patterns are associated with specific autoantibodies and clinical manifestations in JSLE and ASLE patients.

Methods: A retrospective study was performed in Thai children (n = 146) and adults (n = 180) diagnosed with SLE using the Systemic Lupus International Collaborating Clinics classification criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-211218-0465DOI Listing
April 2019
15 Reads
1.255 Impact Factor

[Systemic Lupus Erythematosus].

Authors:
Tetsuya Tsuchida

Brain Nerve 2019 Apr;71(4):317-321

Department of Dermatology, Saitama Medical University.

The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions. LE-specific skin lesions are divided into chronic, subacute, and acute types. The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201268DOI Listing
April 2019
6 Reads

Subacute cutaneous lupus erythematosus leukoderma treated with melanocyte-keratinocyte transplantation procedure.

J Cosmet Dermatol 2019 Dec 1;18(6):1733-1736. Epub 2019 Apr 1.

Dermatology Department, Santa Casa de Curitiba Hospital, Curitiba, Brazil.

Depigmented lesions may occur as postinflammatory sequelae of subacute cutaneous lupus erythematosus (SCLE), leading to great psychosocial impact. A 53-year-old male patient presented with post-SCLE depigmented facial lesions after five years of disease stability. We proposed surgical treatment with melanocyte-keratinocyte transplantation procedure (MKTP), and after five months the patient achieved 90% repigmentation, without Koebner phenomenon (KP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.12942DOI Listing
December 2019
26 Reads

Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

Medicine (Baltimore) 2019 Mar;98(13):e15052

Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, Azienda Ospedaliera Universitaria Senese.

Rationale: Aromatase inhibitors (AIs) are a class of drugs widely used in the treatment of estrogen sensitive breast and ovarian cancer which convert testosterone to estradiol and androstenedione to estrogen. The AIs of third generation, including anastrazole, letrozole and exemestane, have actually become the standard of care of estrogen-receptor-positive breast cancer in menopausal women and are recommended as adjuvant treatment after surgery in place of/or following tamoxifen. Their main side-effects include reduction in bone mineral density, occurrence of menopausal manifestations and development of musculoskeletal symptoms which are, usually, transient, but sometimes evolve into a typical form of arthritis, such as rheumatoid arthritis (RA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455664PMC
March 2019
7 Reads

Left ventricular pseudoaneurysm associated with systemic lupus erythematosus.

Lupus 2019 Apr 24;28(5):681-684. Epub 2019 Mar 24.

1 Division of Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Systemic lupus erythematosus (SLE) is associated with several cardiac manifestations but, to our knowledge, there have been no previously published reports on left ventricular (LV) pseudoaneurysm in this disease. We describe a case of a 30-year-old woman with SLE who presented with a disease flare (acute and subacute cutaneous lupus, pericarditis, fever, leukopenia) associated with heart failure syndrome. The patient was diagnosed with a large LV pseudoaneurysm and a bovine pericardium patch closure was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319837359DOI Listing
April 2019
23 Reads

Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus.

Cytokine 2019 07 20;119:95-112. Epub 2019 Mar 20.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, 14080 Mexico City, Mexico. Electronic address:

We compared the chemokine/receptor expression in skin biopsies of discoid (SLE/DLE) and subacute lupus (SLE/SCLE) and correlated it with tissue and circulating effector CD4 T cells/regulatory cells. Skin biopsies and peripheral blood from 9 active SLE/DLE patients, 9 SLE/SCLE patients, 5 control SLE patients without cutaneous lesions and 10 control healthy donors were included. Clinical skin activity was measured by Cutaneous Lupus Erythematosus Disease Area and Severity Index scoring, and systemic activity was measured by a modified SLEDAI-2K excluding the cutaneous items. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2019.03.010DOI Listing
July 2019
8 Reads

Ustekinumab-induced subacute cutaneous lupus.

JAAD Case Rep 2019 Mar 1;5(3):271-273. Epub 2019 Mar 1.

Dermatology Department, University Hospital Limerick, Limerick, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403108PMC
March 2019
10 Reads

Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors.

Am J Clin Dermatol 2019 Jun;20(3):465-475

Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA.

Objectives: Depression may occur in up to 30% of individuals with cutaneous lupus erythematosus (CLE), many of whom may also have systemic manifestations. Chronic cutaneous lupus erythematosus (CCLE) conditions are less likely to present systemic involvement than acute and subacute conditions but more often cause permanent scarring and dyspigmentation. However, little is known about depression in those who have CCLE confined to the skin (primary CCLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00429-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534449PMC
June 2019
9 Reads

Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study.

J Am Acad Dermatol 2019 Aug 11;81(2):403-411. Epub 2019 Feb 11.

Department of Dermatology, Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Task Force of Dermatopathology, European Academy of Dermatology and Venereology (EADV); SIDEMAST Dermatopathology Study Group, Italian Society of Dermatology.

Background: Clinical and pathologic criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial.

Objective: The aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathologic investigation.

Methods: Eleven European university dermatology units collected all diagnosed cases from January 2000 to December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.009DOI Listing
August 2019
17 Reads
4.449 Impact Factor

Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.

Melanoma Res 2019 06;29(3):338-341

Departments of Dermatology.

Checkpoint blockade immunotherapy has revolutionized the treatment of advanced melanoma, with impressive survival benefits attained through upregulation of the anticancer immune response. Blockade of regulatory checkpoint molecules can, however, also result in aberrant immune activation leading to undesirable inflammation and autoimmunity. Although many genetic determinants have been described in patients with primary autoimmune diseases, it is uncertain whether patients developing autoimmune skin disease as an adverse effect of anti-PD-1 therapy share the same genetic risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000587DOI Listing
June 2019
6 Reads